Kolexia
Salles Jean Pierre Pédiatrie
Salles Jean Pierre
Pédiatrie
Hôpital Paule de Viguier
Toulouse, France
99 Activités
1 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Syndrome de Prader-Willi Hypophosphatasie Maladies osseuses Achondroplasie Rachitisme Obésité Rachitisme hypophosphatémique familial Syndrome de Noonan Hypophosphatémie

Collaborateurs

Voir plus
Edouard Thomas
Edouard Thomas
Hôpital Paule de Viguier, Toulouse, France
Linglart Agnes
Linglart Agnes
Hôpital Bicêtre, Le Kremlin-Bicêtre, France
Gennero Isabelle
Gennero Isabelle
Hôpital Purpan, Toulouse, France
Porquet-Bordes Valerie
Porquet-Bordes Valerie
Hôpital Paule de Viguier, Toulouse, France

Industries

Voir plus
Kyowa Kirin
8 collaboration(s)
Dernière en 2022
Alexion
3 collaboration(s)
Dernière en 2021
Pfizer
2 collaboration(s)
Dernière en 2023
Sandoz
1 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
Prospective Clinical Assessment Study in Children With Achondroplasia (ACH): Prospective Clinical Assessment Study in Children With Achondroplasia: The PROPEL Trial
Essai Clinique (QED Therapeutics, Inc.)   30 janvier 2024
Adult height improved over decades in patients with X-linked hypophosphatemia: a cohort study.
European journal of endocrinology   27 octobre 2023
OR27-03 Oral Infigratinib Treatment Is Well Tolerated And Significantly Increases Height Velocity In Children With Achondroplasia: Month 6 Results From The PROPEL 2 Dose-finding Study
ENDO 2023 Abstracts Annual Meeting of the Endocrine Society   05 octobre 2023
THU181 Evaluation Of Bone Mineral Density In A Cohort Of Children With ACH Participating In The PROPEL 2 Study Of Infigratinib
ENDO 2023 Abstracts Annual Meeting of the Endocrine Society   05 octobre 2023
THU165 PROPEL, PROPEL 2 And PROPEL OLE Studies Of Infigratinib In Children With Achondroplasia: Design And Status Of 3 Ongoing Trials
ENDO 2023 Abstracts Annual Meeting of the Endocrine Society   05 octobre 2023
Growth Hormone Dose Modulation and Final Height in Short Children Born Small for Gestational Age: French Real-Life Data.
Hormone research in paediatrics   11 avril 2023
Study of Infigratinib in Children With Achondroplasia: Phase 2, Open-Label, Dose-Escalation and Dose-Expansion Study of Infigratinib, an FGFR 1-3-Selective Tyrosine Kinase Inhibitor, in Children With Achondroplasia: PROPEL 2
Essai Clinique (QED Therapeutics, Inc.)   06 février 2023
Obesity, Overweight, and Pituitary Stalk Interruption Syndrome in Children and Young Adults.
The Journal of clinical endocrinology and metabolism   26 janvier 2023
Growth hormone treatment improves final height in children with X-linked hypophosphatemia.
Orphanet journal of rare diseases   21 décembre 2022
Off-label use of cinacalcet in pediatric primary hyperparathyroidism: A French multicenter experience.
Frontiers in pediatrics   24 août 2022